Dr. Paul Chew is Senior Vice-President, Chief Science Officer, Chief Medical Officer at Sanofi, US.   Between 2007 and 2009 Dr. Chew held the position of President, U.S. Research & Development and Vice President, Therapeutic Department Head, Metabolism, Diabetes and Thrombosis in which role he was responsible for Lovenox, Lantus, and the therapeutic development portfolio. In addition, he is currently a member of the PhRMA Science & Regulatory Affairs Executive Committee and the Institute of Medicine Value & Science-Driven Healthcare Roundtable.  Prior to Sanofi, US Dr. Chew was Vice-President, Global Head of Metabolism and Diabetes at Aventis Pharmaceuticals, 2001-2004.  

Prior to joining Aventis, Dr. Chew was at the Bristol-Myers Squibb Company, starting in 1992 as Medical Director of Clinical Cardiovascular Development.   Dr. Chew held numerous positions of increasing R&D responsibility at BMS; Dr. Chew was Vice President, U.S. Medical Affairs from 1999-2001 where he was responsible for Plavix, Avapro, Glucophage, and Pravachol.

Prior to industry, Dr. Chew was Assistant Professor of Medicine at The Johns Hopkins Hospital, Attending Physician in Radiology, Director of the Pacemaker Clinic and a member of the Interventional Cardiology staff. Research interests included  acute interventional cardiology, cardiac biomechanics, and statistical modeling of pericardial biomechanics. Dr. Chew obtained his medical education at The Johns Hopkins School of Medicine, serving his internal medicine training and cardiology fellowship at The Johns Hopkins Hospital. Dr. Chew is board-certified in Internal Medicine and Cardiovascular Diseases.